---
title: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD)
euct_id: 2024-513384-15-00
phase: Phase 4
status: Recruiting
sponsor: Denali Therapeutics Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-513384-15-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-513384-15-00"
ctis_last_updated: "2026-05-19T03:34:06.495688743"
source: EU Clinical Trials Information System (CTIS)
---
# Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD)

**EU CT Number:** [2024-513384-15-00](https://euclinicaltrials.eu/ctis-public/view/2024-513384-15-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Recruiting
- **Sponsor:** Denali Therapeutics Inc.
- **Start Date:** 2024-12-01
- **Completion Date:** 2028-02-15
- **Conditions:** Parkinson’s disease, Disease Parkinson's
- **Interventions:** BIIB122, Placebo to BIIB122

## Member States

Trial is authorized in 2 member states: Germany, Spain.

## Sites (10)

- University Hospital Virgen Del Rocio S.L., Sevilla, Spain
- Hospital Universitari Vall D Hebron, Barcelona, Spain
- Hospital Universitario Marques De Valdecilla, Santander, Spain
- Hospital Universitario De La Princesa, Madrid, Spain
- Hospital Universitari General De Catalunya, Sant Cugat Del Valles, Spain
- Hospital Universitario Donostia, Donostia, Spain
- Hospital Clinic De Barcelona, Barcelona, Spain
- Universitaetsklinikum Tuebingen AöR, Tuebingen, Germany
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR, Dresden, Germany
- Universitaetsklinikum Schleswig-Holstein AöR, Luebeck, Germany

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson’s disease; Disease Parkinson's
Age groups: adults 18-64, elderly 65+
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-513384-15-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-513384-15-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-513384-15-00*